{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:49:02Z","timestamp":1773114542296,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069294"],"award-info":[{"award-number":["U10HL069294"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069256"],"award-info":[{"award-number":["U10HL069256"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069249"],"award-info":[{"award-number":["U10HL069249"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069254"],"award-info":[{"award-number":["U10HL069254"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069274"],"award-info":[{"award-number":["U10HL069274"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069278"],"award-info":[{"award-number":["U10HL069278"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069286"],"award-info":[{"award-number":["U10HL069286"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069290"],"award-info":[{"award-number":["U10HL069290"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069291"],"award-info":[{"award-number":["U10HL069291"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069301"],"award-info":[{"award-number":["U10HL069301"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069310"],"award-info":[{"award-number":["U10HL069310"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069315"],"award-info":[{"award-number":["U10HL069315"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069330"],"award-info":[{"award-number":["U10HL069330"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069334"],"award-info":[{"award-number":["U10HL069334"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069348"],"award-info":[{"award-number":["U10HL069348"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL108945"],"award-info":[{"award-number":["U10HL108945"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL108987"],"award-info":[{"award-number":["U10HL108987"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL109137"],"award-info":[{"award-number":["U10HL109137"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL109322"],"award-info":[{"award-number":["U10HL109322"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL109526"],"award-info":[{"award-number":["U10HL109526"]}]},{"name":"National Heart, Lung, and Blood Institute and National Cancer Institute","award":["U10HL069233"],"award-info":[{"award-number":["U10HL069233"]}]},{"name":"National Cancer Institute, National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases","award":["U24-CA076518"],"award-info":[{"award-number":["U24-CA076518"]}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["HHSH250201200016C"],"award-info":[{"award-number":["HHSH250201200016C"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bbmt.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T19:34:44Z","timestamp":1468352084000},"page":"1747-1757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"22","author":[{"name":"Steering Committee of the Blood and Marrow Transplant Clinical Trials Network","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.07.003_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1083-8791(00)70070-X","article-title":"Clinical trials of hematopoietic cell transplantations: current needs and future strategies","volume":"6","author":"O'Reilly","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2006.11.017","article-title":"Blood and Marrow Transplant Clinical Trials Network (BMT CTN): addressing unanswered questions","volume":"13","author":"Weisdorf","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2352-3026(15)00147-7","article-title":"Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study","volume":"2","author":"Anderlini","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbmt.2012.04.014","article-title":"Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels","volume":"18","author":"Tolar","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0030","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the BMT CTN","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0040","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","article-title":"Low risk of chronic graft-versus-host disease and relapse associated with T cell depleted peripheral blood stem cell transplantation for acute myeloid leukemia in first remission: results of the BMT CTN protocol 0303","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0045","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2012-01-403063","article-title":"Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a BMT CTN study","volume":"119","author":"Levine","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute GVHD: a randomized phase II trial from the BMT CTN","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus versus tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0065","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0070","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","article-title":"One- versus two-unit cord blood transplant for leukemia","volume":"371","author":"Wagner","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0075","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.bbmt.2015.06.004","article-title":"Comparison of characteristics and outcomes of trial participants and nonparticipants: example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial","volume":"21","author":"Khera","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation: results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbmt.2014.05.015","article-title":"Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies","volume":"20","author":"Eapen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Phase III study of lenalidomide versus placebo after HCT for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.62.7273","article-title":"A phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103 (Alliance)\/BMT CTN 0502","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the Blood and Marrow Transplant Clinical Trials Network","author":"Laport","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0110","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0115","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2146\/ajhp120599","article-title":"Cost-effectiveness analysis of voriconazole compared with fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants","volume":"70","author":"Mauskopf","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0120","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.bbmt.2014.05.027","article-title":"Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trial Network (BMT CTN) 0902","volume":"20","author":"Jacobsen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0125","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2005-04-1614","article-title":"Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation","volume":"106","author":"Pavletic","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0130","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2007-06-098020","article-title":"Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies","volume":"112","author":"Kurtzberg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0140","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbmt.2014.02.026","volume":"20","author":"Yanik","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0145","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbmt.2009.11.010","article-title":"Mycophenolate pharmacokinetics and association with response to acute GVHD treatment from the BMT CTN","volume":"16","author":"Jacobson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0150","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","article-title":"Characteristics of CliniMACS(\u00ae) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-BMT CTN Protocol 0303","volume":"18","author":"Keever-Taylor","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0155","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","article-title":"Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen","volume":"189","author":"Foley","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bbmt.2012.12.003","article-title":"Lymphocyte phenotype during therapy for acute graft versus host disease: a brief report from BMT-CTN 0302","volume":"19","author":"Bolanos-Meade","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0165","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2013.54.4577","article-title":"Improved survival after transplantation of more donor plasmacytoid dendritic or na\u00efve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201","volume":"32","author":"Waller","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0170","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbmt.2015.02.018","article-title":"Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from BMT CTN 0302 and 0802","volume":"21","author":"Holtan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0180","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2014-06-577023","article-title":"Phase III clinical trial steroids\/mycophenolate mofetil vs steroids\/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802","volume":"124","author":"Bola\u00f1os-Meade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0185","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1086\/421953","article-title":"Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation","volume":"39","author":"Wingard","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1191\/1740774505cn061oa","article-title":"Optimal two-stage randomized phase II clinical trials","volume":"2","author":"Logan","year":"2005","journal-title":"Clin Trials"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0195","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Toxicity committee consensus summary, thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbmt.2007.01.068","article-title":"Editorial: prospective clinical trials in BMT come of age in the US: the Blood and Marrow Transplant Clinical Trials Network","volume":"13","author":"Keating","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0205","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bbmt.2007.08.005","article-title":"BMT CTN State of the Science Symposium 2007","volume":"13","author":"Ferrara","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/1740774508098326","article-title":"Use of biological assignment in hematopoietic stem cell transplantation clinical trials","volume":"5","author":"Logan","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0215","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djp126","article-title":"Re: tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Giralt","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0220","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","article-title":"Graft-versus-host disease treatment: predictors of survival","volume":"16","author":"Levine","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbmt.2010.10.028","article-title":"Optimization of therapy for severe aplastic anemia based on clinical, biological and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the BMT CTN, March 2010","volume":"17","author":"Pulsipher","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbmt.2010.08.020","article-title":"Guidance for developing phase II cell therapy trial proposals for consideration by the BMT CTN","volume":"17","author":"Horwitz","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0235","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/mt.2011.1","article-title":"CARs on track in the clinic: workshop of the BMT CTN sub-committee on cell and gene therapy","volume":"19","author":"Kohn","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2011.07.022","article-title":"Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials","volume":"18","author":"Denzen","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0245","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"Pasquini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0250","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/sim.5597","article-title":"The use of group sequential designs with common competing risks tests","volume":"32","author":"Logan","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0255","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbmt.2013.03.015","article-title":"Anatomy of a successful practice-changing study: a Blood and Marrow Transplant Clinical Trials Network-National Cancer Institute Cooperative Group collaboration","volume":"19","author":"Giralt","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0260","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2013.10.024","article-title":"Health-related QoL of bone marrow versus PBSC donors: a pre-specified subgroup analysis from a phase III RCT BMT CTN protocol 0201","volume":"20","author":"Switzer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbmt.2013.11.006","article-title":"Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007","volume":"20","author":"Ferrara","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/cer.13.95","article-title":"Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer","volume":"3","author":"Roth","year":"2014","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0275","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.bbmt.2014.06.010","volume":"20","author":"Saber","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11899-013-0195-9","article-title":"Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT)","volume":"9","author":"Atallah","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0285","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for donor HLA assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"21","author":"Howard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0290","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbmt.2014.10.003","article-title":"Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014","volume":"21","author":"Appelbaum","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0300","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cncr.29717","article-title":"Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)","volume":"122","author":"Wood","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections following transplantation of bone marrow or peripheral-blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0315","series-title":"Cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group program","author":"National","year":"2010"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0320","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1200\/JCO.2005.05.0104","article-title":"Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials","volume":"24","author":"Dilts","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0325","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2006.06.7819","article-title":"Processes to activate phase III clinical trials in a cooperative oncology Group: the case of Cancer and Leukemia Group B","volume":"24","author":"Dilts","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0330","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1158\/1078-0432.CCR-07-5060","article-title":"Development of clinical trials in a cooperative group setting: the Eastern Cooperative Oncology Group","volume":"14","author":"Dilts","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0335","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-10-1273","article-title":"Phase III clinical trial development: a process of chutes and ladders","volume":"16","author":"Dilts","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0340","first-page":"782","article-title":"Publication of trials funded by the National Heart, Lung, and Blood Institute","volume":"370","author":"Gordon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.07.003_bib0345","doi-asserted-by":"crossref","first-page":"i637","DOI":"10.1136\/bmj.i637","article-title":"Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers","volume":"352","author":"Chen","year":"2016","journal-title":"BMJ"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T11:54:44Z","timestamp":1536580484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116302191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1083879116302191"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}